BioNTech SE (BNTX)
| Market Cap | 26.36B |
| Revenue (ttm) | 2.88B |
| Net Income (ttm) | -540.45M |
| Shares Out | 237.77M |
| EPS (ttm) | -2.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 354,951 |
| Open | 111.13 |
| Previous Close | 111.58 |
| Day's Range | 109.59 - 111.89 |
| 52-Week Range | 76.53 - 131.49 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | 133.79 (+20.66%) |
| Earnings Date | Nov 4, 2024 |
About BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinic... [Read more]
Financial Performance
In 2023, BioNTech SE's revenue was 3.82 billion, a decrease of -77.94% compared to the previous year's 17.31 billion. Earnings were 930.30 million, a decrease of -90.14%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $133.79, which is an increase of 20.66% from the latest price.
News
BioNTech's Oncology Gamble: High Stakes, Big Potential
BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March, outp...
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024...
Health Rounds: mRNA vaccine shows promise against C. difficile in animal study
Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to-treat Clostridioides difficile bacteria, using the technology behind the r...
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
BioNTech (BNTX) Presents at Innovation Series: AI Day
BioNTech SE (NASDAQ:BNTX) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer, BioNTech Ryan...
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence (“AI”) subsidiary InstaDeep Ltd . (“InstaDe...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...
BioNTech Is More Than a Covid-19 Stock. It's Having a Great September.
Recently BioNTech has been boosted a wave of enthusiasm over another company's cancer drug, which has turned the biopharma industry upside down.
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day, ...
Trade It or Fade It: The week's big biotech moves
Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ivones...
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the Europ...
Tempus Announces Real World Data Collaboration with BioNTech
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collabor...
BioNTech BNT116 Lung Cancer mRNA Vaccine Clinical Trials Initiated
Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Trials Says Kuick Research Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Tri...
FDA approves new updated COVID-19 vaccines to target KP.2 variant. Here's what to know
The Food and Drug Administration (FDA) has approved new formulations of COVID-19 vaccines from Moderna and Pfizer-BioNTech. These updated vaccines are specifically tailored to target the KP.2 strain, ...
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, w...
Lung cancer vaccine trials launched: What you need to know about BNT116
In a significant breakthrough, the world's first mRNA lung cancer vaccine trials have been launched across seven countries, marking a new era in cancer treatment. This innovative vaccine, known as BN...
Lung cancer patient is first in UK to receive experimental vaccine
A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease.
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved...
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Partial clinical hold of BioNTech SE's BNT326/YL202 for the treatment of patients with solid tumors in phase 1 study was lifted by the FDA. The primary endpoint of ORR of BNT111 in combination with Li...
BioNTech says FDA lifts partial hold on its cancer drug trial
BioNTech on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its experimental cancer drug.
Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 of 2 Endpoints
Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' combined...
Pfizer, BioNTech COVID-19-flu combination drug meets 1 of 2 trial objectives
Pfizer Inc. PFE, -0.59% and BioNTech SE BNTX, +2.83% said Friday a Phase 3 trial of their COVID-19-influenza vaccine candidate met one of its two objectives. The companies said the candidate showed “c...
Pfizer, BioNtech say combined flu-COVID vaccine misses a main goal of Phase 3 trial
Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals and...
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate ...